Sonoma Pharmaceuticals, Inc.
SNOA
$3.24
-$0.03-0.92%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 25.02% | 17.43% | 12.19% | 13.51% | 11.81% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 25.02% | 17.43% | 12.19% | 13.51% | 11.81% |
| Cost of Revenue | 26.73% | 18.30% | 10.43% | 14.80% | 1.24% |
| Gross Profit | 22.31% | 16.01% | 15.17% | 11.29% | 34.17% |
| SG&A Expenses | -0.19% | -1.98% | -2.83% | 5.28% | -9.06% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 12.53% | 6.99% | 3.22% | 10.07% | 1.58% |
| Operating Income | 27.06% | 21.62% | 21.08% | -0.54% | 21.24% |
| Income Before Tax | 8.61% | 31.13% | 42.22% | 26.86% | 38.59% |
| Income Tax Expenses | 205.36% | 2,470.59% | 380.61% | 128.57% | -200.00% |
| Earnings from Continuing Operations | 5.62% | 22.04% | 28.50% | 26.16% | 40.06% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 5.62% | 22.04% | 28.50% | 26.16% | 40.06% |
| EBIT | 27.06% | 21.62% | 21.08% | -0.54% | 21.24% |
| EBITDA | 27.53% | 21.66% | 21.06% | -1.05% | 21.94% |
| EPS Basic | 55.28% | 75.57% | 78.94% | 79.41% | 83.69% |
| Normalized Basic EPS | 57.57% | 77.65% | 82.09% | 79.23% | 83.02% |
| EPS Diluted | 55.28% | 75.57% | 78.94% | 79.41% | 83.69% |
| Normalized Diluted EPS | 57.57% | 77.65% | 82.09% | 79.23% | 83.02% |
| Average Basic Shares Outstanding | 99.00% | 137.49% | 172.97% | 225.63% | 266.16% |
| Average Diluted Shares Outstanding | 99.00% | 137.49% | 172.97% | 225.63% | 266.16% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |